C4 Therapeutics (C4 Therapeutics) 1-Year ROIIC %

: 26.17% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. C4 Therapeutics's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was 26.17%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for C4 Therapeutics's 1-Year ROIIC % or its related term are showing as below:

CCCC's 1-Year ROIIC % is ranked better than
62.46% of 1457 companies
in the Biotechnology industry
Industry Median: -1.95 vs CCCC: 26.17

C4 Therapeutics 1-Year ROIIC % Historical Data

The historical data trend for C4 Therapeutics's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

1-Year ROIIC %

Get a 7-Day Free Trial

32.26

-424.03

-13.26

110.56

26.17

C4 Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
1-Year ROIIC %	Get a 7-Day Free Trial															110.56	39.25	67.82	94.27	26.17

Competitive Comparison

For the Biotechnology subindustry, C4 Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

C4 Therapeutics 1-Year ROIIC % Distribution

For the Biotechnology industry and Healthcare sector, C4 Therapeutics's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where C4 Therapeutics's 1-Year ROIIC % falls into.

C4 Therapeutics 1-Year ROIIC % Calculation

C4 Therapeutics's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

1-Year ROIIC %	=	1-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	1-Year Incremental Invested Capital
	=	( -140.3935038 (Dec. 2023) - -129.534 (Dec. 2022) )	/	( 135.339 (Dec. 2023) - 176.833 (Dec. 2022) )
	=	-10.8595038	/	-41.494
	=	26.17%^***

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

C4 Therapeutics (NAS:CCCC) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

C4 Therapeutics 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of C4 Therapeutics's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

C4 Therapeutics (C4 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4 Therapeutics Inc (NAS:CCCC) » Definitions » 1-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472

Website

https://www.c4therapeutics.com

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

Executives

Mark Mossler	officer: Chief Accounting Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Kendra Adams	officer: Chief Financial Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Leonard Reyno	officer: Chief Medical Officer	607 NORTH LAS PALMAS AVENUE, LOS ANGELES CA 90004
Utpal Koppikar	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Donna Roy Grogan	director	1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Laura Bessen	director	4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Andrew Hirsch	director, officer: See Remarks	C/O BIND THERAPEUTICS, INC., 325 VASSAR ST, CAMBRIDGE MA 02139
Kelly Schick	officer: Chief People Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott N Boyle	officer: Chief Business Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Malcolm Salter	director	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Adam Crystal	officer: Chief Medical Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Elena Prokupets	director	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel	officer: Chief Legal Officer	C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher	officer: Chief Scientific Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Lauren White	officer: Chief Financial Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472